Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285095 | 0.98 | CYP2B6 (0.47) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 | |
| SCHEMBL10647110 | 0.98 | CYP2B6 (0.47) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 | |
| SCHEMBL22939999 | 0.98 | CYP2B6 (0.47) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 | |
| SCHEMBL14723543 | 0.98 | CYP2B6 (0.47) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 | |
| Water SCHEMBL28907403 | 0.96 | CYP2B6 (0.46) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 | |
| SCHEMBL10068593 | 0.95 | — | — | |
| SCHEMBL945421 | 0.90 | — | — | |
| Ammonia Solution, Strong SCHEMBL28860953 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL28498519 | 0.88 | CYP19A1 (0.39) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 | |
| SCHEMBL27449735 | 0.87 | CYP19A1 (0.36) | CYP2B6CYP19A1CYP3A4CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | claimed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | claimed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | claimed |
| CN-107074807-A | Compositions and methods for inhibiting histone demethylase | 吉利德科学公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9390864-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| CN-105121439-A | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders | PFIZER | 2015-12-02 | — | — | CN | disclosed |
| US-20150340165-A1 | ADDITIVES FOR DYE-SENSITIZED SOLAR CELLS | MERCK PATENT GMBH (DE) | 2015-11-26 | — | — | US | disclosed |
| US-9159499-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| US-7314701-B2 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20050095527-A1 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2005-05-05 | — | — | US | disclosed |
| US-4731363-A | Thromboxane synthase inhibitors as insulin lowering agents and antiobesity agents | HOFFMANN-LA ROCHE INC. (US) | 1988-03-15 | — | — | US | disclosed |
| US-4591594-A | INSULIN LOWERING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | CFD, TFPI, F12 | CYP2B6 1252/4885CYP19A1 1378/4885CYP3A4 996/4885 |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CYP2B6 3168/4885CYP19A1 3129/4885CYP3A4 3574/4885 |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CYP2B6 2980/4885CYP19A1 1758/4885CYP3A4 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.